KalVista Pharmaceuticals, Inc. (KALV) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
200 Crossing Boulevard
Framingham, MA 01702
United States of America (the)
Phone
857 999 0075
Website
Sector
Healthcare
Industry
Biotechnology
Employees
275
First IPO Date
April 09, 2015
| Name | Title | Pay | Year Born |
| Benjamin L. Palleiko | Chief Executive Officer & Director | 1.15M | 1966 |
| Bilal Arif | Chief Operating Officer | 572,458 | 1972 |
| Brian Piekos | Chief Financial Officer | 638,486 | 1975 |
| Christopher Yea | Chief Development Officer | 708,532 | 1964 |
| Paul K. Audhya | Chief Medical Officer | 773,445 | 1972 |
| Brian Krex | General Counsel | 0 | 1968 |
| Rachel Morten | Senior Vice President of Regulatory Affairs & QA | 0 | N/A |
| Jarrod Aldom | Vice President of Corporate Communications | 0 | N/A |
| Ryan Baker | Head of Investor Relations | 0 | N/A |
| Christopher L. Hamblett | Senior Vice President of Corporate Development | 0 | N/A |
| Linea Aspesi | Chief People Officer | 0 | 1970 |
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.